MA35615B1 - Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf - Google Patents

Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf

Info

Publication number
MA35615B1
MA35615B1 MA36908A MA36908A MA35615B1 MA 35615 B1 MA35615 B1 MA 35615B1 MA 36908 A MA36908 A MA 36908A MA 36908 A MA36908 A MA 36908A MA 35615 B1 MA35615 B1 MA 35615B1
Authority
MA
Morocco
Prior art keywords
inhibitor
raf
cancer
treatment
compositions
Prior art date
Application number
MA36908A
Other languages
English (en)
Inventor
Carlos Garcia-Echeverria
Loïc Vincent
Angela Virone-Oddos
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46851503&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA35615(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA35615B1 publication Critical patent/MA35615B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne des compositions contenant au moins un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf, et au moins un inhibiteur de pi3kb, ainsi que leurs utilisations en vue du traitement du cancer.
MA36908A 2011-09-16 2014-04-10 Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf MA35615B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11306172A EP2570127A1 (fr) 2011-09-16 2011-09-16 Compositions et procédés pour traiter le cancer avec un inhibiteur bêta PI3KB et un inhibiteur de la voie MAPK, incluant des inhibiteurs MEK et RAF
PCT/EP2012/068072 WO2013037943A1 (fr) 2011-09-16 2012-09-14 Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf

Publications (1)

Publication Number Publication Date
MA35615B1 true MA35615B1 (fr) 2014-11-01

Family

ID=46851503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA36908A MA35615B1 (fr) 2011-09-16 2014-04-10 Compositions et méthodes utilisables en vue du traitement du cancer et faisant appel à un inhibiteur de pi3k bêta et à un inhibiteur de la voie mapk, dont, notamment, les inhibiteurs ciblant mek et raf

Country Status (26)

Country Link
US (1) US20140275078A1 (fr)
EP (2) EP2570127A1 (fr)
JP (1) JP2014530181A (fr)
KR (1) KR20140062143A (fr)
CN (1) CN103889418A (fr)
AR (1) AR087902A1 (fr)
AU (1) AU2012307309A1 (fr)
BR (1) BR112014005839A2 (fr)
CA (1) CA2847091A1 (fr)
CL (1) CL2014000606A1 (fr)
CO (1) CO6910192A2 (fr)
CR (1) CR20140102A (fr)
DO (1) DOP2014000046A (fr)
EA (1) EA201490638A1 (fr)
EC (1) ECSP14013244A (fr)
GT (1) GT201400038A (fr)
IL (1) IL231212A0 (fr)
MA (1) MA35615B1 (fr)
MX (1) MX2014003223A (fr)
NI (1) NI201400020A (fr)
PE (1) PE20141035A1 (fr)
PH (1) PH12014500536A1 (fr)
SG (1) SG11201400380XA (fr)
TN (1) TN2014000086A1 (fr)
UY (1) UY34341A (fr)
WO (1) WO2013037943A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2976106T3 (da) * 2013-03-21 2021-06-14 Array Biopharma Inc Kombinationsterapi, som omfatter en b-raf-hæmmer og en anden hæmmer
CA2908640A1 (fr) * 2013-04-05 2014-10-09 Sanofi Composition anti-tumorale comprenant un inhibiteur selectif de pi3k beta et un inhibiteur selectif de pi3k alpha
WO2015051252A1 (fr) * 2013-10-03 2015-04-09 Duke University Compositions et méthodes destinées à traiter les cancers ayant une activité jak2
US10028958B2 (en) 2014-04-19 2018-07-24 Massachusetts Institute Of Technology Methods of treating cancer with a combination of selected MEK1/2 and AXL inhibitors
CN110291089B (zh) 2017-01-17 2022-05-27 海帕瑞吉尼克斯股份有限公司 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂
KR101950094B1 (ko) 2017-07-28 2019-02-19 이성재 보릿대 공예품 제작방법
CN113440616A (zh) * 2020-03-25 2021-09-28 上海科州药物研发有限公司 Ras或raf突变型癌症的联合疗法
CN120204228B (zh) * 2025-04-17 2026-01-30 重庆医科大学附属第一医院 化合物或其盐在制备癌症治疗药物中的用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
DK2395004T3 (en) 2005-06-22 2016-03-21 Plexxikon Inc Pyrrolo [2,3-b] pyridine derivatives as protein kinase inhibitors
FR2951169B1 (fr) * 2009-10-09 2011-12-02 Sanofi Aventis Nouveaux derives de (6-oxo-1,6-dihydro-pyrimidin-2-yl)-amide, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de phosphorylation d'akt(pkb)
NZ597579A (en) 2009-07-02 2013-06-28 Sanofi Sa Novel (6-oxo-1, 6-dihydro-pyrimidin-2-yl)-amide derivatives, preparation thereof, and pharmaceutical use thereof as akt(pkb) phosphorylation inhibitors

Also Published As

Publication number Publication date
DOP2014000046A (es) 2014-07-15
CO6910192A2 (es) 2014-03-31
CA2847091A1 (fr) 2013-03-21
UY34341A (es) 2013-04-05
MX2014003223A (es) 2014-06-05
CR20140102A (es) 2014-05-07
EP2755653A1 (fr) 2014-07-23
WO2013037943A8 (fr) 2013-07-18
WO2013037943A1 (fr) 2013-03-21
SG11201400380XA (en) 2014-04-28
US20140275078A1 (en) 2014-09-18
JP2014530181A (ja) 2014-11-17
AU2012307309A1 (en) 2014-04-03
IL231212A0 (en) 2014-04-30
KR20140062143A (ko) 2014-05-22
TN2014000086A1 (en) 2015-07-01
AR087902A1 (es) 2014-04-23
CL2014000606A1 (es) 2014-11-07
PH12014500536A1 (en) 2019-08-07
GT201400038A (es) 2014-12-16
BR112014005839A2 (pt) 2017-03-28
CN103889418A (zh) 2014-06-25
EP2570127A1 (fr) 2013-03-20
ECSP14013244A (es) 2014-07-31
PE20141035A1 (es) 2014-09-04
NI201400020A (es) 2014-04-23
EA201490638A1 (ru) 2014-08-29

Similar Documents

Publication Publication Date Title
CR20130267A (es) Inhibidores de nampt y rock
EA201592223A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA SERPINAl И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
MX374547B (es) Método para mejorar las inmunoterapias especifícas en el tratamiento contra el cáncer.
EA201690406A1 (ru) Селективные ингибиторы grp94 и способы их применения
EA201592225A1 (ru) КОМПОЗИЦИИ НА ОСНОВЕ iRNA TMPRSS6 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
TR201816379T4 (tr) DNA-PK inhibitörleri.
MX378277B (es) Metodo para tratar cancer usando una combinacion de inhibidores de chk1 y relacionado con atm y rad3 (atr).
ECSP12012097A (es) Derivados de fumarato de ácido graso y sus usos
GB201114051D0 (en) Compounds and their uses
BR112013027500A2 (pt) liberação controlada de imunossupressores de nanotransportadores sintéticos
MX360349B (es) Composiciones y metodos para inhibir la expresion del gen de proteasa transmembrana, serina 6 (tmprss6).
ECSP14030779A (es) Inhibidores del nampt
MX349886B (es) Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
EP2576536A4 (fr) Inhibiteurs de la prostaglandine d2 synthase hématopoïétique
BR112013028420A2 (pt) tratamento de mieloma múltiplo
EA202091676A1 (ru) Способ лечения потери костной массы альвеолярного отростка посредством применения антител к склеростину
TN2014000086A1 (en) Compositions and methods for treating cancer using pi3k beta inhibitor and mapk pathway inhibitor, including mek and raf inhibitors
EA201400748A1 (ru) Композиция для обработки семян
EA201690756A1 (ru) Составы кускового моющего средства с улучшенным смягчающим действием на кожу, содержащие неионную полимерную структурирующую систему
FR2961402B1 (fr) Compositions contenant des arabinoxylo-oligosaccharides et leurs utilisations
WO2013013302A8 (fr) Létalité synthétique et traitement anticancéreux
CL2018001719A1 (es) Tratamiento contra el mieloma múltiple (divisional solicitud 201600396)
MX2015012455A (es) Metodo para el tratamiento de la enfermedad de higado graso.
EA201500752A1 (ru) Способ лечения заболеваний
CO6670519A2 (es) Métodos para tratar infecciones bacterianas recurrentes